BBA
Baker Bros. Advisors Portfolio holdings
AUM
$10.3B
This Quarter Return
+27.7%
1 Year Return
+63.34%
3 Year Return
+231.6%
5 Year Return
+293.68%
10 Year Return
+1,612.7%
AUM
$18.4B
AUM Growth
+$18.4B
(+10%)
Cap. Flow
-$969M
Cap. Flow
% of AUM
-5.27%
Top 10 Holdings %
Top 10 Hldgs %
90.4%
Holding
120
New
7
Increased
23
Reduced
7
Closed
13
Top Buys
| 1 |
Revolution Medicines
RVMD
|
$53.5M |
| 2 |
SWTX
SpringWorks Therapeutics
SWTX
|
$31.5M |
| 3 |
Roivant Sciences
ROIV
|
$30M |
| 4 |
FibroGen
FGEN
|
$23.6M |
| 5 |
BPMC
Blueprint Medicines
BPMC
|
$15M |
Top Sells
Sector Composition
| 1 | Healthcare | 99.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Summit Therapeutics
SMMT
$17.7B
| $11M | 0.06% |
6,304,705
+4,304,705
| +215% | +$7.53M |
|
|
ADAP
52
Adaptimmune Therapeutics
ADAP
$14.7M
| $10.7M | 0.06% |
9,830,877
| – | – |
|
|
OPT
53
DELISTED
Opthea Limited American Depositary Shares
OPT
| $10.6M | 0.06% |
2,691,391
| – | – |
|
54
Verastem
VSTM
$576M
| $10.6M | 0.06% |
25,521,447
-1,467,451
| -5% | -$609K |
|
55
Fate Therapeutics
FATE
$116M
| $9.53M | 0.05% |
1,671,717
+1,456,022
| +675% | +$8.3M |
|
|
PNT
56
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
| $8.5M | 0.05% |
1,169,103
| – | – |
|
|
BLUE
57
DELISTED
bluebird bio
BLUE
| $7.95M | 0.04% |
2,499,715
| – | – |
|
58
Allogene Therapeutics
ALLO
$251M
| $7.79M | 0.04% |
+1,576,901
| New | +$7.79M |
|
59
Mersana Therapeutics
MRSN
$36M
| $7.75M | 0.04% |
+1,886,115
| New | +$7.75M |
|
|
WHWK
60
Whitehawk Therapeutics, Inc. Common Stock
WHWK
$88.1M
| $7.17M | 0.04% |
989,928
| – | – |
|
61
Sera Prognostics
SERA
$128M
| $6.85M | 0.04% |
1,789,000
+1,587,438
| +788% | +$6.08M |
|
62
Geron
GERN
$906M
| $6.64M | 0.04% |
+3,061,224
| New | +$6.64M |
|
63
Sana Biotechnology
SANA
$736M
| $6.54M | 0.04% |
+2,000,000
| New | +$6.54M |
|
|
ARAV
64
DELISTED
Aravive, Inc. Common Stock
ARAV
| $6.52M | 0.04% |
3,261,224
| – | – |
|
65
MacroGenics
MGNX
$121M
| $6.4M | 0.03% |
892,579
| – | – |
|
66
Alector
ALEC
$279M
| $5.97M | 0.03% |
964,851
+282,860
| +41% | +$1.75M |
|
67
Athira Pharma
ATHA
$15.2M
| $5.88M | 0.03% |
2,350,355
+470,519
| +25% | +$1.18M |
|
68
Insmed
INSM
$30.6B
| $5.85M | 0.03% |
343,000
+323,050
| +1,619% | +$5.51M |
|
69
TScan Therapeutics
TCRX
$102M
| $5.85M | 0.03% |
2,784,792
| – | – |
|
70
Natera
NTRA
$23.3B
| $5.55M | 0.03% |
100,000
| – | – |
|
71
Compass Therapeutics
CMPX
$470M
| $5.09M | 0.03% |
1,557,630
| – | – |
|
|
AFMD
72
DELISTED
Affimed
AFMD
| $4.92M | 0.03% |
6,596,830
| – | – |
|
73
Relay Therapeutics
RLAY
$683M
| $4.68M | 0.03% |
+284,000
| New | +$4.68M |
|
|
BCEL
74
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
| $4.03M | 0.02% |
3,532,760
| – | – |
|
75
Century Therapeutics
IPSC
$41.4M
| $3.99M | 0.02% |
1,149,340
| – | – |
|